Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA-Based VC Firm Invests in Therapeutics, Devices, and Diagnostics Companies with Strong IP & Management Teams Across All Indications

21 Jan

A venture capital firm based in USA has about one third of their investments in healthcare. The firm is a fairly opportunistic investor, and looks for companies that have a strong IP position and a strong management team. The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies, but they get most excited about companies leveraging new technologies and/or with the potential for platform business models.  The firm generally invests in seed-series A rounds , investing $500k-3M in rounds generally in the range of $2 to $15 million. The firm prefers to invest companies that have some clinical data. The firm will invest globally, but prefers to invest in companies based in the US.

The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies. Historically, the firm has invested in health technologies driven by breakthroughs in AI, materials science or nanotechnology, and will not invest in a digital technology that does not have strong IP. The firm is generally agnostic to indication. The firm generally does not invest in consumer-facing/telehealth-related digital health companies.

The firm looks for companies with strong IP and management teams. The firm is willing to lead or co-invest, but will generally not participate in rounds larger than $30M. When acting as a lead investor, the firm is a very active investor, and plays a large role in helping company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Taiwan VC Invests in Early-Stage Devices, Diagnostics, Digital Health Companies Based in Taiwan and USA

21 Jan

An early-stage venture capital firm based in Taiwan was formed by a group of successful entrepreneurs, and specializes in incubation, seed and early venture investments in technology-heavy sectors. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm is open to either leading a financing round or joining a syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company for projects they led.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Impact VC Seeks All Life Science Companies that Target CNS Diseases, Investing Up to $8M Per Deal

21 Jan

An impact venture capital firm dedicated to funding private, early-stage whose innovation(s) significantly help or cure patients suffering from psychiatric and/or neurological diseases. The firm will invest in Seed and Series A rounds, typically allocating $200k – 8 million USD for each deal. The firm looks for deals globally and plans to make several investments in the upcoming year immediately following the first close of the fund. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on improving the treatment or curing diseases of the central nervous system. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered.

The firm sometimes prefers to take a board seat in companies in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan Headquartered Global Company Invests in Medtech & Digital Health Companies in CNS, Oncology, Cardiovascular Diseases, and More

21 Jan

A firm headquartered in Tokyo, Japan, operates globally and providing medical solutions in more than 160 countries. Their venture funding activities are based in several offices throughout USA and China. Typical allocation sizes range from $1M-$10M, and may be structured as research funds, equity, or convertible loans depending on the phase of development. The firm will consider companies at all stages from concept to commercial.

The firm is interested in medical technology, diagnostics and digital health companies across indications including cardio, neuro, and peripheral vascular diseases, heart failure, stroke and oncology.

The firm may or may not seek a board seat on companies they invest in. They are open to working with all management teams, and view deals globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based VC Invests in Seed Stage, Consumer-Facing and Enterprise Technologies in Digital Health

7 Jan

An early-stage seed fund focuses on seed stage and sometimes Series A. Typical equity allocations range from $500 – 750 K per company. The firm is open to both leading and co-investing. The firm has been investing from a $50M fund and is currently raising a new fund, from which it expects to make new investments.  The firm is seeking opportunities from across the US with a focus on the Bay Area.

The firm invests across multiple industries including healthcare IT. The firm prefers products that do not require FDA approval. Within healthcare IT, the firm considers both consumer-facing and enterprise solutions that demonstrate customer traction and large market potential.

The firm can work with incomplete management teams and would require a board seat on a case-by-case basis. The firm has funded companies in which the founders were either current students or recent graduates from top US universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Newly Established Investment Arm of Health System Invests in Digital Health Technologies With Strategic Alignment

7 Jan

A newly established investment funding arm of a USA-based non-profit health system seeks to foster the commercialization of internal ideas as well as external innovation. The firm made its first investment in September 2020, and expect to close 2 more investments in the next 3 months. To date, the firm has been focusing in Series A to B rounds but expect to look into more early-stage opportunities in the future. Initial size of investment can range from $500K – 1M. The firm invests off balance sheet and has no dedicated fund. The firm is focused on partnering and investing in companies based in the USA.

The firm is interested in piloting and investing in technologies that strategically align with the interests of a large integrated delivery network. This includes both the organization’s existing priority areas, along trying to improve the firm’s strategic position in the future. Areas of interest include improving the ratings and member retention in their Medicaid and Medicare Advantage insurance plans, recruiting and retaining clinicians, process optimization, the coming consumerization of healthcare, back-office optimization, and more. The firm is primarily looking for digital health solutions, but will consider some 510k medical devices. The firm is not interested in therapeutics or diagnostics.

The firm has no specific company or management team requirements. The firm prefers to co-invest alongside syndicate partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Arm of Europe HQ Corporate Invests Over $10M in Diagnostics and Monitoring Device Companies in USA, Europe and China

7 Jan

A corporate venture capital arm of a Europe-based corporate is focused on financial returns as well as bringing strategic value to the corporate. The firm makes equity investments in seed through growth rounds ranging from €1M-€5M for typical initial investments and may invest up to €10M-€12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10%-25% stake in the company. The firm is currently investing out of its third fund of €150M with a total of €450M AUM, and makes 10 investments per year. The firm focuses on North American, European, Chinese and Israeli companies.

The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection, a connected blood glucose monitor and an enhanced PCR technology (laser PCR). The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.

The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: